Should patients with haemophilia receive gene therapy?

Thierry VandenDriessche; Kohei Tatsumi; Midori Shima

doi:10.1016/S2352-3026(22)00300-3

Should patients with haemophilia receive gene therapy?

Thierry VandenDriessche, Kohei Tatsumi, Midori Shima

Research output: Contribution to journal › Comment/debate

2 Citations (Scopus)

Original language	English
Pages (from-to)	e722-e723
Journal	The Lancet. Haematology
Volume	9
Issue number	10
DOIs	https://doi.org/10.1016/S2352-3026(22)00300-3
Publication status	Published - Oct 2022

Bibliographical note

Funding Information:
TVD declares funding from Pfizer and Catalyst Biosciences; speaker fees from Takeda, Pfizer, and BioMarin; research grants from European Union Horizon 2020 UPGRADE project and Vrije Universiteit Brussel IOF GEAR; and patents on vector designs for haemophilia gene therapy. TVD thanks Glenn Pierce, David Lillicrap, and Alok Srivastava for helpful comments. MS declares grants from Chugai, CSL-Behring, Takeda; consulting fess from Chugai, Fujimoto, and UniQure; and speaker fees from Chugai, Roche, Novo Nordisk, CSL-Behring, Sanofi, Bayer and Fujimoto. KT declares grants or research support from Grants-in-Aid for Scientific Research (KAKENHI), Japan Blood Products Organization, The Mother and Child Health Foundation, and Novo Nordisk.

Copyright:
Copyright 2023 Elsevier B.V., All rights reserved.

Keywords

Genetic Therapy
Hemophilia A/genetics
Humans

Access to Document

10.1016/S2352-3026(22)00300-3

Handle.net

Persistent link

Cite this

@article{a11db172fc07458ba0cd21ac99d28aa9,

title = "Should patients with haemophilia receive gene therapy?",

keywords = "Genetic Therapy, Hemophilia A/genetics, Humans",

author = "Thierry VandenDriessche and Kohei Tatsumi and Midori Shima",

note = "Funding Information: TVD declares funding from Pfizer and Catalyst Biosciences; speaker fees from Takeda, Pfizer, and BioMarin; research grants from European Union Horizon 2020 UPGRADE project and Vrije Universiteit Brussel IOF GEAR; and patents on vector designs for haemophilia gene therapy. TVD thanks Glenn Pierce, David Lillicrap, and Alok Srivastava for helpful comments. MS declares grants from Chugai, CSL-Behring, Takeda; consulting fess from Chugai, Fujimoto, and UniQure; and speaker fees from Chugai, Roche, Novo Nordisk, CSL-Behring, Sanofi, Bayer and Fujimoto. KT declares grants or research support from Grants-in-Aid for Scientific Research (KAKENHI), Japan Blood Products Organization, The Mother and Child Health Foundation, and Novo Nordisk. Copyright: Copyright 2023 Elsevier B.V., All rights reserved.",

year = "2022",

month = oct,

doi = "10.1016/S2352-3026(22)00300-3",

language = "English",

volume = "9",

pages = "e722--e723",

journal = "The Lancet. Haematology",

issn = "2352-3026",